— In this paper we describe our experience in the treatment of impotence with intracavernous self-injection of prostaglandin E1 in 55 diabetic patients. Overall results show that 49 out of the 55 (89%) patients are satisfied with this method of treatment and have continued to use it for more than 3 years. Two thirds of the partners also reported an improvement in their sexual life. Complications were no more frequent than in non-diabetic men and were all of a minor nature.
GiorgiP.M., CanaleD., TurchiP.: Recent diagnostic and therapeutic aspects in male sexual impotence. Recenti Prog. Med., 83: 614–620, 1992.
2.
PriceD.E., O'MalleyB.P., JamesM.A.: Why are impotent diabetic men not being treated?Practical Diabetes, 8: 1–10, 1991.
3.
McCullochD.K., YoungR.J., PrescottR.J.: The natural history of impotence in diabetic men. Diabetologia, 26: 437–440, 1984.
4.
FairburnC.G., McCullochD.K., WuF.C.: The effects of diabetes on male sexual function. Clinics in Endocrinology and Metabolism, 11: 749–767, 1982.
5.
McCullochD.K., HoskingD.J., TobertA.: A pragmatic approach to sexual dysfunction in diabetic men: psychosexual counselling. Diabetic Med., 3: 485–489, 1986.
6.
QuadriR., ZanoweM., MavleS.: Is it possible to prevent andrological complications in the diabetic patient?Arch. Ital. Urol. Nefrol. Androl., 63: 435–439, 1991,.
7.
WilsonS.K., WahmanG.E., LangeJ.L.: Eleven years’ experience with the inflatable penile prosthesis. J. Urol., 139: 951–952, 1988.
8.
BejaniD.E., PeritoP.E., LusgartenM., RhamyR.K.: Gangrene of the penis after implantation of penile prosthesis: case reports, treatment recommendations and review of the literature. J. Urol., 150: 190–191, 1993.
9.
PriceD.E., CookseyG., JehuD.: The management of impotence in diabetic men by vacuum tumescence therapy. Diabetic. Med., 8: 964–967, 1991.
10.
LevineS.B., AlthofS.E., TurnerL.A.: Side effects of self-administration of intracavernous papaverine and phentolamine for the treatment of impotence. J. Urol., 141: 54, 1989.
11.
GirdleyF.M., BruskewitzR.C., FeyziJ.: Intracavernous self injection for impotence. J. Urol., 140: 972, 1988.
12.
WattersG.R., KeoghE.Y., EarleC.M.: Experience in the management of erectile dysfunction using the intra-cavernosal self injection of vasoactive drugs. J. Urol., 140: 1917, 1988.
13.
EarleC.M., KeoghE.J., WisjiewskiZ.S., TullochA.G.S.: Prostaglandin E1 therapy for impotence comparison with papaverine. J. Urol., 143: 57, 1990.
14.
LeeL.M., StevensonR.W.D., SzaszG.: Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double blind comparison. J. Urol., 141: 549, 1989.
15.
SchrameckP., DorningerR., WaldhauserM.: Prostaglandin E, in erectile dysfunction. Efficiency and incidence of priapism. Brit. J. Urol., 65: 68, 1990.
16.
OlsonL.D., WinternityW.W.: Hypopituitarism: a complication of diabetes. South Med. J., 70: 411, 1977.
17.
BezwodaW.R., BothwellT.H., Van der WaltL.A.: An investigation of gonadal dysfunction in patients with idiopathic haemochromatosis. Clin. Endocrinol., 6: 377, 1977.
18.
StiefC.G., DjamilianM., AntonP.: Single potential analysis of cavernous electrical activity in impotent patients: a possible diagnostic method for autonomic cavernous dysfunction and cavernous smooth muscle degeneration. J. Urol., 1416: 771–776, 1991.
19.
AriellyJ., WeinbergD., EisenkraftS.: Intracavernous auto-injection of prostaglandin E1 for diagnostic evaluation and treatment of patients with erectile dysfunction. Harefuah (Journal of Israel Medical Association), 126: 369–372, 1994.
20.
MurrayF.T., GeisserM.E., CohenM.S., WilliamsR.S.: Evaluation and treatment of sexual dysfunction in men with diabetes mellitus. J. Fla. Med. Assoc, 78: 757–761, 1991.
21.
AliS.T., ShalknR.N., SiddigiN.A., SiddigiP.S.: Comparative studies of the induction of erectile response to film and fantasy in diabetic men with and without neuropathy. Arch. Androl., 30: 137–145, 1993.
22.
DjamilianM.H., TrussM.C., TanH.K.: Single potential analysis of cavernous electrical activity (space). Experiences, limitations and perspectives. Ann. Urol. Paris, 27: 136–143, 1993.
23.
WangC.J., ShenS.J., WuC.C., HuangC.H., ChiangC.P.: Penile blood flow study in diabetic impotence. Urol. Int., 50: 209–212, 1993.
24.
PriceD.E.: Impotence in diabetes (editorial). B.M.J.: 307: 275–276, 1993.
25.
VodusekD.B., Ravnik-OblakM., OblakC.: Pudendal versus limb nerve electro-physiological abnormalities in diabetics with erectile dysfunction. Int. J. Impot. Res., 5: 37–42, 1993.
26.
MelmanA., RiccardiR.: The success of microsurgical penile revascularization in treating arteriogenic impotence. Int. J. Imp. Res, 5: 47–52, 1993.
27.
CummingJ., PryorJ.P.: Treatment of organic impotence. Br. J. Urol., 67: 640–643, 1991.
28.
IshiN., WatanabeH., IrisawaC., KikuchiJ.: Therapeutic trial with prostaglandin E1 for organic impotence. In: Proceedings of the Second World Congress of Impotence. Prague, The Netherlands, Abstract 11.2, June 17–20, 1986.
29.
LueT.F., TanaghoE.A.: Physiology of erection and pharmacological management of impotence. J. Urol., 137: 829, 1987.
30.
GolubM., ZiaP., Matsunom, HortonR.: Metabolism of prostaglandins A1 and E1 in man. J. Clin. Invest., 59: 1404, 1975.
